SG Americas Securities LLC Raises Stock Position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

SG Americas Securities LLC grew its holdings in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) by 57.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 94,671 shares of the company’s stock after buying an additional 34,469 shares during the quarter. SG Americas Securities LLC owned 0.06% of Xeris Biopharma worth $321,000 at the end of the most recent reporting period.

Several other hedge funds have also recently made changes to their positions in XERS. Geode Capital Management LLC increased its stake in Xeris Biopharma by 2.9% during the third quarter. Geode Capital Management LLC now owns 3,333,470 shares of the company’s stock worth $9,502,000 after acquiring an additional 93,091 shares during the last quarter. AQR Capital Management LLC increased its position in shares of Xeris Biopharma by 4.6% during the 2nd quarter. AQR Capital Management LLC now owns 1,193,080 shares of the company’s stock valued at $2,684,000 after purchasing an additional 52,074 shares during the last quarter. Walleye Capital LLC purchased a new stake in Xeris Biopharma during the 3rd quarter valued at $3,197,000. Wellington Management Group LLP lifted its position in Xeris Biopharma by 11.7% in the third quarter. Wellington Management Group LLP now owns 471,644 shares of the company’s stock worth $1,344,000 after buying an additional 49,535 shares during the last quarter. Finally, JPMorgan Chase & Co. boosted its stake in Xeris Biopharma by 20.8% during the third quarter. JPMorgan Chase & Co. now owns 391,960 shares of the company’s stock worth $1,117,000 after buying an additional 67,557 shares during the period. 42.75% of the stock is currently owned by hedge funds and other institutional investors.

Xeris Biopharma Price Performance

XERS stock opened at $3.64 on Wednesday. The company has a market capitalization of $542.65 million, a PE ratio of -8.09 and a beta of 2.61. Xeris Biopharma Holdings, Inc. has a 12 month low of $1.69 and a 12 month high of $3.87. The firm’s 50-day moving average is $3.43 and its 200 day moving average is $3.05.

Analysts Set New Price Targets

XERS has been the topic of several recent analyst reports. Jefferies Financial Group reissued a “buy” rating and issued a $6.00 target price (up previously from $4.00) on shares of Xeris Biopharma in a research note on Wednesday, January 29th. Piper Sandler downgraded shares of Xeris Biopharma from an “overweight” rating to a “neutral” rating and set a $3.00 price objective for the company. in a research note on Monday, November 11th. Finally, HC Wainwright upped their target price on Xeris Biopharma from $6.00 to $6.60 and gave the company a “buy” rating in a research note on Monday, November 11th.

Xeris Biopharma Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.